Treatment decisions involving Procarbazine are closely tied to the disease settings recorded here: Hodgkin lymphoma; gliomas in PCV regimens. Causes DNA damage through reactive metabolites and interferes with nucleic-acid synthesis. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. It is categorized as Chemotherapy; Alkylating-like Agent, with Hodgkin Lymphoma; Glioma listed as the principal tumor types. The regimen field includes ABVD alternatives; MOPP; PCV. Those combinations are clinically meaningful because the same medicine can have a different role when paired with endocrine therapy, chemotherapy, another targeted agent, or supportive treatment. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. For clinicians reviewing the database, the drug name should therefore be interpreted together with histology, stage, prior therapy, and the relevant biomarker or eligibility requirement. Its pharmacologic class provides useful context, but does not replace disease-specific selection criteria. The wording is intended as a reference synthesis rather than a prescribing protocol and deliberately avoids individualized dose recommendations. Oncology approvals and guideline-supported uses can change over time, so contemporary labeling remains important.